## Cellular pathology audit template

|  |  |
| --- | --- |
| Date of completion  | (To be inserted when completed) |
| Name of lead author/participants | (To be inserted) |
| Specialty | Histopathology/genitourinary |
| Title | **Audit of prostate cancer reporting** |
| Background | Datasets published by the Royal College of Pathologists define the core data items that should be included in histopathology reports to ensure all necessary data is provided.In 2024, the College’s *Dataset for histopathology reports for prostatic carcinoma* was published, which lists and discusses the data items to be included when reporting prostatic biopsy specimens.1 |
| Aim & objectives | This audit template is a tool to determine whether pathological core data items are included in histopathology reports in prostatic biopsy specimens. |
| Standards & criteria | **Criteria range:** 100%, or if not achieved, there is documentation in the text of the report that explains the variance.**The agreed standards:** Each core data item stated in the dataset for inclusion in histology reports of prostatic biopsy specimens should be included in the histology reports. |
| Method | **Sample selection:** (To be completed by the author)All cases of prostatic cancer within the time period from …. to … Data to be collected from proformas and textual histology reports for resected specimens.Data from either or all: prostate core biopsies/transurethral resections (TURP)/radical prostatectomies.**Data to be collected on proforma (see below).** |
| Results | (To be completed by the author)The results of this audit show the following compliance with the standards.**Prostatic core biopsies**

|  |  |
| --- | --- |
| **Core data items** | % compliance |
| **Clinical information** |  |
| Prostate specific antigen (PSA) |  |
| MRI findings |  |
| Number of cores taken |  |
| **Macroscopic description** |  |
| Number of cores |  |
| Location |  |
| **Microscopic** |  |
| Histological type |  |
| Number of cores involved – right/left/target |  |
| Longest length of tumour in any 1 core |  |
| Invasive cribriform or intraductal carcinoma (IDC) |  |
| Perineural invasion |  |
| Extraprostatic extension |  |
| Gleason sum score |  |
| Grade group |  |
| Percentage pattern 4 |  |
| Representative block for molecular studies with % tumour content |  |
| SNOMED |  |

**TURP**

|  |  |
| --- | --- |
| **Core data items** | % compliance |
| **Clinical information** |  |
| PSA |  |
| Type of specimen |  |
| **Macroscopic description** |  |
| Specimen weight |  |
| **Microscopic** |  |
| Histological type |  |
| Gleason score |  |
| Grade group |  |
| Percentage pattern 4 |  |
| Invasive cribriform or IDC |  |
| Prostatic tissue involved by tumour |  |
| Representative block for molecular studies with % tumour content |  |
| TNM stage |  |
| SNOMED |  |

**Radical prostatectomies**

|  |  |
| --- | --- |
| **Core data items** | % compliance |
| **Clinical information** |  |
| PSA |  |
| Type of specimen |  |
| **Macroscopic description** |  |
| Specimen weight |  |
| Lymph nodes |  |
| **Microscopic** |  |
| Histological type |  |
| Gleason score |  |
| Grade group |  |
| Extraprostatic extension (EPE) status with extent |  |
| Bladder neck status |  |
| Seminal vesicle invasion |  |
| Margin status – with location and extent |  |
| Vascular invasion |  |
| Invasive cribriform or IDC |  |
| Representative block for molecular studies with % tumour content |  |
| TNM stage |  |
| If lymph nodes – number positive and diameter of largest deposit |  |
| SNOMED |  |

**Commentary:** |
| Conclusion | (To be completed by the author) |
| Recommend-ations for improvement | Present the result with recommendations, actions and responsibilities for action and a timescale for implementation. Assign a person(s) responsible to do the work within a timeframe.**Some suggestions:**highlight areas of practice that are differentpresent findings. |
| Action plan | (To be completed by the author – see attached action plan proforma) |
| Re-audit date | (To be completed by the author) |
| Reference | 1. Royal College of Pathologists. *Dataset for histopathology reports for prostatic carcinoma.* Accessed November 2024. Available at: <https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html>
 |

## Data collection proforma for prostate cancer reporting

## Audit reviewing practice

Patient name:

Hospital number:

Date of birth:

Consultant:

Case number:

**For prostate cores:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Standards** | **1****Yes**  | **2****No** | **3** If no, was there documentation to explain the variance? **Yes/No** plus free-text comment | **4** Compliant with guideline based on **Yes** from column 1 or an appropriate explanation from column 3. **Yes/No** |
| **Clinical information** |  |  |  |  |
| PSA |  |  |  |  |
| MRI findings |  |  |  |  |
| Number of cores taken |  |  |  |  |
| **Macroscopic description** |  |  |  |  |
| Number of cores |  |  |  |  |
| Location |  |  |  |  |
| **Microscopic** |  |  |  |  |
| Histological type |  |  |  |  |
| Number of cores involved – right/left/target |  |  |  |  |
| Longest length of tumour in any 1 core |  |  |  |  |
| Invasive cribriform or IDC |  |  |  |  |
| Perineural invasion |  |  |  |  |
| Extraprostatic extension |  |  |  |  |
| Gleason sum score |  |  |  |  |
| Grade group |  |  |  |  |
| Percentage pattern 4 |  |  |  |  |
| Representative block for molecular studies with % tumour content |  |  |  |  |
| SNOMED |  |  |  |  |

**For TURPs**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Standards** | **1****Yes**  | **2****No** | **3** If no, was there documentation to explain the variance? **Yes/No** plus free-text comment | **4** Compliant with guideline based on **Yes** from column 1 or an appropriate explanation from column 3. **Yes/No** |
| **Clinical information** |  |  |  |  |
| PSA |  |  |  |  |
| Type of specimen |  |  |  |  |
| **Macroscopic description** |  |  |  |  |
| Specimen weight |  |  |  |  |
| **Microscopic** |  |  |  |  |
| Histological type |  |  |  |  |
| Gleason score |  |  |  |  |
| Grade group |  |  |  |  |
| Percentage pattern 4 |  |  |  |  |
| Invasive cribriform or IDC |  |  |  |  |
| Prostatic tissue involved by tumour |  |  |  |  |
| Representative block for molecular studies with % tumour content |  |  |  |  |
| TNM stage |  |  |  |  |
| SNOMED |  |  |  |  |

**For radical prostatectomies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Standards** | **1****Yes**  | **2****No** | **3** If no, was there documentation to explain the variance? **Yes/No** plus free-text comment | **4** Compliant with guideline based on **Yes** from column 1 or an appropriate explanation from column 3. **Yes/No** |
| **Clinical information** |  |  |  |  |
| PSA |  |  |  |  |
| Type of specimen |  |  |  |  |
| **Macroscopic description** |  |  |  |  |
| Specimen weight |  |  |  |  |
| Lymph nodes |  |  |  |  |
| **Microscopic** |  |  |  |  |
| Histological type |  |  |  |  |
| Gleason score |  |  |  |  |
| Grade group |  |  |  |  |
| EPE Status with extent |  |  |  |  |
| Bladder neck status |  |  |  |  |
| Seminal vesicle invasion |  |  |  |  |
| Margin status – with location and extent |  |  |  |  |
| Vascular invasion |  |  |  |  |
| Invasive cribriform or IDC |  |  |  |  |
| Representative block for molecular studies with % tumour content |  |  |  |  |
| TNM stage |  |  |  |  |
| If lymph nodes – number positive and diameter of largest deposit |  |  |  |  |
| SNOMED |  |  |  |  |

|  |
| --- |
| **Audit action plan** An audit of prostate cancer reporting |
| Audit recommendation | Objective | Action | Timescale | Barriers and constraints | Outcome | Monitoring |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |